Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Oral Oncol ; 148: 106649, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38035508

ABSTRACT

INTRODUCTION: Head and neck cancer ranks as the seventh most common cancer worldwide. Proton therapy is widely used in head and neck cancer. Osteoradionecrosis(ORN) is currently a commonly investigated side effect of proton therapy. A meta-analysis is needed to investigate this topic. MATERIAL/METHODS: Two authors searched three databases, including PubMed, Embase, and Cochrane Library; the search period was from inception to June 2023. The search keyword was set to be ((("osteoradionecrosis") OR ("osteonecrosis")) AND ("proton")). RESULTS: We initially collected 410 articles, and after article selections, 22 articles remained in our systematic reviews. Due to the overlapping of patient populations, 17 studies were finally included in our meta-analysis. The pooled grade 3 or more ORN rate is 0.01(95 % CI = 0.01-0.03). Subgroup analysis showed that IMPT didn't reduce grade 3 or more ORN compared with 3DCPT (p = 0.15). CONCLUSIONS: Our meta-analysis showed that severe ORN rarely occurred in proton therapy for head and neck cancer patients.


Subject(s)
Head and Neck Neoplasms , Osteoradionecrosis , Proton Therapy , Humans , Osteoradionecrosis/etiology , Proton Therapy/adverse effects , Head and Neck Neoplasms/radiotherapy , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...